Codeine Facts
Opioid;
Description
Codeine (3-methylmorphine) is a naturally-occurring opioid of the morphinan class. Codeine itself binds opioid receptors only weakly;[1] it is morphine that suppresses pain and produces the sedation and warmth characteristic of opioids.
Subjective effects include pain suppression, sedation, mild euphoria, anxiolysis, a sense of diffuse warmth, and cognitive slowing. The overall experience is a quieter version of morphine — gentle and tranquil — but its intensity varies dramatically between individuals based on how efficiently genetics convert codeine to morphine.[2]
Codeine produces moderate physical and psychological dependence, and its main toxicity risk is respiratory depression driven by morphine.[3] The defining danger is genetic: people who convert codeine to morphine unusually fast can experience life-threatening effects from standard doses — a trait present in up to 18% of some populations.[4]
Dose and durationby route · individual sensitivity varies
Starts in 30 – 45 minLasts 3 – 6 hoursAfter-effects 2 – 4 hours
Body and dependence
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Physical dependence
- Moderate
- Psychological dependence
- Moderate
- Withdrawal
- Mild
- Compulsive redosing
- Moderate
Tolerance
- Builds
- Moderate
- Fully resets after
- 10 days
- Carries over to
- morphine;
heroin; oxycodone; hydrocodone; fentanyl; tramadol; dihydrocodeine
Effectslikely at a common dose
- Perception
- Sleep-transition hallucinations;
+4 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise - Body
- Pain suppression;
Tactile euphoria; Sedation; Constipation; Pupil constriction; Bodily heaviness; Body high; Breathing alteration; Muscle relaxation; Physical fatigue; +15 possible, including Respiratory depression, Nausea, Dizziness - Thinking
- Thought deceleration;
Cognitive fatigue; Cognitive impairment; Focus suppression; Information processing suppression; +8 possible, including Analysis suppression, Decision impairment, Compulsive redosing urge - Feeling
- Anxiety suppression;
Euphoria; +1 possible - Self
- none likely · 4 possible, including Communication suppression, Craving
- Time
- none likely · 2 possible, including Temporal disorientation
Who shouldn't take it
Combinations62 recorded
Seek help immediately if
- Unresponsive / can't be woken, even to a firm sternal rub
- Slow, shallow, or stopped breathing
- Pinpoint pupils
- Blue/grey lips, fingertips, or skin (cyanosis)
- Limp body; pale, clammy skin
- Choking or gurgling sounds ("death rattle")
- Slow, erratic, or absent pulse
What to do
- Try to wake them — shout their name, firm sternal rub
- Call emergency services immediately
- Administer naloxone if available
- Give rescue breaths (or CPR if there is no pulse)
- Place them in the recovery position
- Stay with them; re-dose naloxone every 2–3 minutes if there is no response
- Reversal agent
- Naloxone (Narcan) — opioid antagonist. May require repeated doses; its effect can wear off before the opioid does.
With prompt naloxone and rescue breathing, reversal is usually rapid. Because naloxone can wear off before the opioid — especially with long-acting opioids (methadone) or high-potency ones (fentanyl) — a period of monitoring is needed even after the person revives.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^Volpe DA, McMahon Tobin GA, Mellon RD, et al. (2011) Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs — Regulatory Toxicology and Pharmacology doi:10.1016/j.yrtph.2010.12.007
- [2]^Eddy NB, Friebel H, Hahn KJ, Halbach H (1968) Codeine and its alternates for pain and cough relief. I. Codeine, exclusive of its antitussive action — Bulletin of the World Health Organization PMID:4972938
- [3]^Frost J, Helland A, Nordrum IS, Slordal L (2012) Investigation of morphine and morphine glucuronide levels and cytochrome P450 isoenzyme 2D6 genotype in codeine-related deaths — Forensic Science International doi:10.1016/j.forsciint.2012.01.019
- [4]^Kim TD, Kwak JS, Shin JG, et al. (2025) CYP2D6 genotyping in a Korean cohort: comparative analysis with Asian, Caucasian, and African populations — Pharmacogenomics doi:10.1080/14622416.2025.2565993